diPGA: Treatment of Type 2 Diabetes Mellitus with Adiponectin (ADN)
* Author to whom correspondence should be addressed.
Adiponectin (ADN) is a protein hormone secreted by adipose tissues. Correlations have been discovered between low ADN plasma levels and insulin resistance with increased fasting glucose levels. In order to be diagnosed with T2D, individuals will be given an A1C Hemoglobin test, where a result of 6.5% or higher on two separate occasions constitutes diagnoses. Recent trends depict diabetes, specifically T2D, as a world wide epidemic. Researchers have found genetic markers as factors contributing to the acquisition of T2D, particularly in the Hispanic demographic. The gene associated with diabetes among Hispanics is a specific locus, known as SLC16A11, found in the 17th chromosome of the human genome. The pathogenesis of SLC16A11alters the carrier’s ability to metabolize lipids and increases their intracellular triacylglycerol levels. The locus was traced back to ancestral mating among Homo sapiens and Neanderthals. A gene therapy medication known as diPGA, was constructed replicating the SLC16A11 locus and attaching ADN and IGF-1 onto receptor sites, and tested among Hispanic subjects throughout Miami-Dade County. Subjects were given the medication to observe if increasing ADN levels in individuals would have an adverse affect on fasting glucose levels (A1C%). Results illustrated that Experimental Groups receiving diPGA showed a significant upward spike in ADN levels, rising steadily and stabilizing during a span of 36 months. Adversely, a negative correlation was noted in reference to fasting glucose levels (A1C%), showing steady decrease and stabilization towards the cessation of the 36-month trial. The results of this clinical trial raise implications that can positively impact the scientific, medical, and Hispanic communities worldwide if successfully replicated in future studies.